Prøve GULL - Gratis
Hotspots & growth opportunities in biomanufacturing
Chronicle Pharmabiz
|November 27, 2025
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
The country has also witnessed an exponential rise in biotech startups in the past decade, as shown in Figure 1 below: India witnessed an almost 200-fold increase in biotech startups in the past 10 years.
The launch of Government of India policies such as BIRAC funding schemes (BIG (Biotechnology Ignition Grant), SEED (Sustainable Entrepreneurship and Enterprise Development) and LEAP (Launching Entrepreneurs for Affordable Products), the BioE3 Policy (India's "Biotechnology for Economy, Environment, and Employment" policy) and e-platforms such as Startup India have significantly accelerated the growth of the innovation ecosystems for Indian biotech post-2017.
As shown in Figure 2, Karnataka, Tamil Nadu and Maharashtra are the leading biotech hubs in Indial. In September 2025, the Government of India launched High Performance Biomanufacturing Platforms, a joint initiative of the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC).This newly launched network comprising advanced biofoundries and biomanufacturing hubs will use tools such as synthetic biology, omics technologies, artificial intelligence, machine learning to advance developments across the Indian biotech, healthcare, agriculture, energy, climate, and food industries.
India already has over 21 biofoundries, compared to a global hub of 100, which positions India as an important innovation hotspot in global biomanufacturing space.Key drivers and challenges impacting Indian biomanufacturing sector
The Indian Government is currently focused on six thematic sectors for driving biomanufacturing growth, which are shown below:
Denne historien er fra November 27, 2025-utgaven av Chronicle Pharmabiz.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Chronicle Pharmabiz
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
